Table 2.
Cumulative incidence rate of local recurrence in entire patients
| Variables | % | |
|---|---|---|
| Overall | 3.2 | |
| Age | 0.003 | |
| <35 years | 8.7 | |
| ≥35 years | 2.8 | |
| Menstruation | 0.414 | |
| premenopausal | 3.4 | |
| postmenopausal | 2.9 | |
| BMI | 0.756 | |
| <18.5 kg/m2 | 7.6 | |
| 18.5-22.9 kg/m2 | 2.9 | |
| 23-24.9 kg/m2 | 2.3 | |
| 25-29.9 kg/m2 | 3.7 | |
| ≥30 kg/m2 | 5.4 | |
| Laterality | 0.688 | |
| left | 3.4 | |
| right | 3.0 | |
| Location | 0.804 | |
| outer | 3.0 | |
| inner | 3.8 | |
| Operation | 0.162 | |
| breast conserving | 3.5 | |
| mastectomy | 1.9 | |
| FMS | <0.001 | |
| ≥2 mm | 2.2 | |
| <2 mm | 8.7 | |
| HG | 0.014 | |
| 1 | 0.9 | |
| 2 | 2.7 | |
| 3 | 4.6 | |
| Hormone receptor | <0.001 | |
| ER and/or PR+ | 1.8 | |
| ER- and PR- | 8.3 | |
| HER2 | <0.001 | |
| negative | 2.4 | |
| overexpressed | 7.9 | |
| Subtypes | <0.001 | |
| luminal A | 1.4 | |
| luminal B | 5. 6 | |
| HER2-enriched | 10.7 | |
| triple negative | 7.1 | |
| T stage | 0.528 | |
| 1 | 3.0 | |
| 2 | 3.7 | |
| N stage | 0.513 | |
| 0 | 3.4 | |
| 1 | 2.5 | |
| AJCC stage | 0.943 | |
| I | 3.1 | |
| II | 3.3 | |
| Chemotherapy | 0.723 | |
| no | 3.2 | |
| yes | 3.2 | |
| Radiotherapy | 0.513 | |
| no | 2.3 | |
| breast only | 3.6 | |
| breast + SCL | 0 |
BMI, body mass index; FMS, final margin status; HG, histologic grade; LVSI, lymphovascular space invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor type 2; AJCC, American Joint on Cancer Committee; SCL, supraclavicular lymph node.